(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 5.84% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.48%.
Amneal Pharmaceuticals's revenue in 2025 is $2,852,914,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $945,483,308,500, with the lowest AMRX revenue forecast at $944,628,070,541, and the highest AMRX revenue forecast at $946,886,300,773. On average, 3 Wall Street analysts forecast AMRX's revenue for 2026 to be $998,813,975,168, with the lowest AMRX revenue forecast at $985,769,319,227, and the highest AMRX revenue forecast at $1,011,275,699,911.
In 2027, AMRX is forecast to generate $1,068,387,881,460 in revenue, with the lowest revenue forecast at $1,028,452,697,321 and the highest revenue forecast at $1,108,323,065,599.